Literature DB >> 16225664

Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia.

Marina Bousquet, Christian Recher, Cathy Queleen, Cecile Demur, Bernard Payrastre, Pierre Brousset.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16225664     DOI： 10.1111/j.1365-2141.2005.05784.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

Review 1.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

Authors:  Sophie Park; Nicolas Chapuis; Jérôme Tamburini; Valérie Bardet; Pascale Cornillet-Lefebvre; Lise Willems; Alexa Green; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

2.  Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type.

Authors:  Linzhu Zhai; Yuanyuan Zhao; Sheng Ye; He Huang; Ying Tian; Qiuliang Wu; Hanliang Lin; Tongyu Lin
Journal:  Tumour Biol       Date:  2011-06-10

Review 3.  Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.

Authors:  Elias Jabbour; Oliver G Ottmann; Michael Deininger; Andreas Hochhaus
Journal:  Haematologica       Date:  2014-01       Impact factor: 9.941

4.  PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation.

Authors:  Raoul Tibes; Steven M Kornblau; Yihua Qiu; Spyro M Mousses; Christiane Robbins; Tracy Moses; John D Carpten
Journal:  Br J Haematol       Date:  2007-12-05       Impact factor: 6.998

Review 5.  The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

Authors:  Alberto M Martelli; Camilla Evangelisti; Francesca Chiarini; James A McCubrey
Journal:  Oncotarget       Date:  2010-06

6.  Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase.

Authors:  Marco Colamonici; Gavin Blyth; Diana Saleiro; Amy Szilard; Meghan Bliss-Moreau; Francis J Giles; Jessica K Altman; Elspeth M Beauchamp; Leonidas C Platanias
Journal:  Oncotarget       Date:  2015-04-10

7.  Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.

Authors:  David Chiron; Peter Martin; Maurizio Di Liberto; Xiangao Huang; Scott Ely; Brian J Lannutti; John P Leonard; Christopher E Mason; Selina Chen-Kiang
Journal:  Cell Cycle       Date:  2013-05-15       Impact factor: 4.534
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.